德尔塔
您当前所在位置:首页 > 定制产品 > 糖化学

「同位素标记抑制剂」Betahistine-13C,d3 dihydrochloride

发布时间:2025-06-10     作者:德尔塔生物   分享到:

【产品介绍】:

生物活性:Betahistine-13C,d3 (dihydrochloride) is the 13C- and deuterium labeled Betahistine (dihydrochloride). Betahistine dihydrochloride is an orally active histamine H1 receptor agonist and a H3 receptor antagonist[1]. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA)[3].
IC50 & Target:H1 Receptor
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[32].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Betahistine-13C,d3 dihydrochloride 相关抗体:
ADGRE1 (F4/80) Antibody (YA002)
ADGRE1 (F4/80) Antibody (YA920)
分子量:213.13
Formula:C713CH11D3Cl2N2
非标记 CAS:5579-84-0
中文名称:盐酸倍他司汀-13C,d3;倍他司丁二盐酸盐-13C,d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (529 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Poyurovsky M, et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3.
 [Content Brief]
[3]. Gbahou F, et al. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.J Pharmacol Exp Ther. 2010 Sep 1;334(3):945-54.
 [Content Brief]
[4]. Tang KT, et al. Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses.Int Immunopharmacol. 2016 Oct;39:236-245.
 [Content Brief]